Savara (SVRA) Other Non-Current Assets (2010 - 2026)

Savara (SVRA) reported Other Non-Current Assets of $11.4 million for Q1 2026, up 5.88% year-over-year from $10.7 million in Q1 2025, and down 2.34% on a QoQ basis from $11.6 million in Q4 2025.

Savara (SVRA) has 17 years of Other Non-Current Assets data on file, last reported at $11.4 million in Q1 2026.

  • Quarterly Other Non-Current Assets rose 5.88% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (up 5.88% YoY) and the FY2025 annual result came in at $11.6 million, up 12.97% from the prior year.
  • Other Non-Current Assets retreated to $11.4 million in Q1 2026 per SVRA's latest filing, from $11.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $11.6 million in Q4 2025 and bottomed at $116000.0 in Q4 2022.
  • The 5-year median for Other Non-Current Assets is $10.3 million (2024), against an average of $6.7 million.
  • The widest annual swing landed in 2022, when Other Non-Current Assets plunged 98.97%; it then surged 9348.28% in 2023.
  • Tracing SVRA's Other Non-Current Assets over 5 years: stood at $116000.0 in 2022, then surged by 9348.28% to $11.0 million in 2023, then declined by 6.02% to $10.3 million in 2024, then advanced by 12.97% to $11.6 million in 2025, then decreased by 2.34% to $11.4 million in 2026.
  • Per Business Quant, the three latest SVRA Other Non-Current Assets figures stand at $11.4 million (Q1 2026), $11.6 million (Q4 2025), and $990000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 12.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 60,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.26 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.13 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 63.55 Mn
10 Savara 1.30 Bn 1.30 Bn - 11.36 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 11.36 Mn
Dec 31, 2025 11.64 Mn
Sep 30, 2025 990,000.00
Jun 30, 2025 1.03 Mn
Mar 31, 2025 10.73 Mn
Dec 31, 2024 10.30 Mn
Sep 30, 2024 11.11 Mn
Jun 30, 2024 10.63 Mn
Mar 31, 2024 1.15 Mn
Dec 31, 2023 10.96 Mn
Sep 30, 2023 10.50 Mn
Jun 30, 2023 888,000.00
Mar 31, 2023 868,000.00
Dec 31, 2022 116,000.00
Sep 30, 2022 9.75 Mn
Jun 30, 2022 952,000.00
Mar 31, 2022 11.06 Mn
Dec 31, 2021 11.27 Mn
Sep 30, 2021 1.05 Mn
Jun 30, 2021 11.83 Mn
Mar 31, 2021 1.03 Mn
Dec 31, 2020 250,000.00
Sep 30, 2020 11.64 Mn
Jun 30, 2020 11.16 Mn
Mar 31, 2020 1.31 Mn
Dec 31, 2019 11.11 Mn
Sep 30, 2019 1.65 Mn
Jun 30, 2019 221,000.00
Mar 31, 2019 2.29 Mn
Dec 31, 2018 131,000.00
Sep 30, 2018 54,000.00
Jun 30, 2018 11.61 Mn
Mar 31, 2018 1.06 Mn
Dec 31, 2017 33.63 Mn
Sep 30, 2017 91,000.00
Jun 30, 2017 99,000.00
Mar 31, 2017 131,000.00
Dec 31, 2016 10.48 Mn
Sep 30, 2016 6.50 Mn
Jun 30, 2016 131,000.00
Mar 31, 2016 141,000.00
Dec 31, 2015 8.55 Mn
Sep 30, 2015 8.55 Mn
Jun 30, 2015 8.55 Mn
Mar 31, 2015 8.55 Mn
Dec 31, 2014 8.55 Mn
Sep 30, 2014 363,497.00
Jun 30, 2014 63,497.00
Mar 31, 2014 83,542.00
Dec 31, 2013 60,000.00
Sep 30, 2013 6.55 Mn
Jun 30, 2013 6.55 Mn
Mar 31, 2013 6.55 Mn
Dec 31, 2012 6.55 Mn
Sep 30, 2012 43,912.00
Jun 30, 2012 6.55 Mn
Mar 31, 2012 43,912.00
Dec 31, 2011 6.55 Mn
Sep 30, 2011 48,311.00
Jun 30, 2011 6.55 Mn
Dec 31, 2010 33,484.00